Display Settings:

Format

Send to:

Choose Destination

    Mutagenesis. 1992 Sep;7(5):329-33.

    Comparison of 32P-postlabelling and cytogenetic analysis of human blood treated in vitro with melphalan.

    Routledge MN, Garner RC, Kirsch-Volders M.

    Jack Birch Unit for Environmental Carcinogenesis, Department of Biology, University of York, Heslington, UK.

    Various 32P-postlabelling methods have been evaluated for the detection of melphalan-DNA (mel-DNA) adducts in melphalan treated calf thymus DNA and human blood treated in vitro with melphalan. When the butanol extraction procedure was used for the postlabelling studies, increasing adduct levels were seen between 0.01 and 1.0 micrograms/ml melphalan (maximum adduct value = 3.29/10(8) nucleotides at 1.5 micrograms/ml melphalan). The labelling efficiency, however, was thought to be low. Human blood treated in vitro with a dose range of melphalan from 0.01 to 1.5 micrograms/ml was analysed for micronuclei, sister chromatid exchanges, chromosome aberrations and DNA adducts. A correlation was seen between mel-DNA adducts and cytogenetic damage for each of the endpoints studied.

    PMID: 1470027 [PubMed - indexed for MEDLINE]

    LinkOut - more resources

    Full Text Sources:

    Molecular Biology Databases:

    Supplemental Content

    Click here to read

    Patient drug information

    • Melphalan (Alkeran®)

      Your doctor has ordered the drug melphalan to help treat your illness. The drug can be taken as tablets by mouth on an empty stomach or it can be given by injection into a vein.